1. A PHASE 1/2 STUDY OF PIXANTRONE, ETOPOSIDE, BENDAMUSTINE AND, IN CD20+ TUMORS, RITUXIMAB IN PATIENTS WITH RELAPSED AGGRESSIVE B‐ OR T‐CELL LYMPHOMAS—THE P[R]EBEN STUDY. (June 2017) Authors: d'Amore, F.; Leppä, S.; Larsen, T.S.; Brown, P.; Relander, T.; Mannisto, S.; Jørgensen, J.M.; Holte, H.; Lauritzsen, G.F.; Enblad, G.; Toldbod, H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 423 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY. (12th June 2019) Authors: Maurer, M.J.; Jakopsen, L.H.; Habermann, T.M.; Nowakowski, G.S.; Ansell, S.M.; Thompson, C.A.; Brown, P.D.; Jørgensen, J.M.; Frederiksen, H.; Syrbu, S.; Feldman, A.L.; Novak, A.J.; Rimsza, L.M.; Cerhan, J.R.; El‐Galaly, T.C.; Link, B.K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 231 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R2‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL. (12th June 2019) Authors: Nowakowski, G.; Willenbacher, W.; Greil, R.; Larsen, T.S.; Patel, K.; Jäger, U.; Manges, R.F.; Trümper, L.; Haioun, C.; Everaus, H.; Kalakonda, N.; Knoble, J.; de Nully Brown, P.; Jørgensen, J.M.; Cunningham, D.; Domper Rubio, N.; Casadebaig, M.; Manzke, O.; Munoz, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗